triple agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
The Moscow Institute of Physics and Technology, also known as Phystech, has taught numerous Nobel Prize winners, including Pyotr Kapitsa, Nikolay Semyonov, Lev Landau, and Alexander Prokhorov the Fyodorov Eye Microsurgery Complex, founded in 1988 by Russian eye surgeon Svyatoslav Fyodorov the Moscow Aviation Institute the Moscow Motorway Institute (State Technical University) the Moscow Engineering Physics Institute, known for its research in nuclear physics the Combined Arms Academy of the Armed Forces of the Russian Federation, Russia's highest military school Although Moscow has a number of well-known Soviet-era higher educational institutions—most of which are oriented towards engineering or fundamental sciences—in recent years, the city has a growing number of commercial and private institutions that offer classes in business and management. Many state institutions have expanded their educational scope and introduced new courses or departments. Institutions in Moscow, like the rest of post-Soviet Russia, have begun to offer new international certificates and postgraduate degrees, including the Master of Business Administration. In addition, student exchange programs with many countries—especially in Europe—have become widespread in Moscow's universities. Finally, schools in Moscow offer seminars, lectures, and courses for corporate employees and businessmen.
High doses of some antioxidants may have harmful long-term effects. The Beta-Carotene and Retinol Efficacy Trial (CARET) study of lung cancer patients found that smokers given supplements containing beta-carotene and vitamin A had increased rates of lung cancer. These harmful effects may also be seen in non-smokers, as one meta-analysis including data from approximately 230,000 patients showed that β-carotene, vitamin A or vitamin E supplementation is associated with increased mortality, but saw no significant effect from vitamin C. No health risk was seen when all the randomized controlled studies were examined together, but an increase in mortality was detected when only high-quality and low-bias risk trials were examined separately. As the majority of these low-bias trials dealt with either elderly people, smokers, or people with disease, these results may not apply to the general population. This meta-analysis was later repeated and extended by the same authors, confirming the previous results. These two publications are consistent with some previous meta-analyses that also suggested that vitamin E supplementation increased mortality, and that antioxidant supplements increased the risk of colon cancer. In the Selenium and Vitamin E Cancer Prevention Trial (SELECT study), vitamin E – alone or combined with selenium – had no effect on the risk of prostate cancer. Beta-carotene may also increase lung cancer.
=== Screening === Two main approaches exist for the finding of new bioactive chemical entities from natural sources. The first is sometimes referred to as random collection and screening of material, but the collection is far from random. Biological (often botanical) knowledge is often used to identify families that show promise. This approach is effective because only a small part of the earth's biodiversity has ever been tested for pharmaceutical activity. Also, organisms living in a species-rich environment need to evolve defensive and competitive mechanisms to survive. Those mechanisms might be exploited in the development of beneficial drugs. A collection of plant, animal and microbial samples from rich ecosystems can potentially give rise to novel biological activities worth exploiting in the drug development process. One example of successful use of this strategy is the screening for antitumor agents by the National Cancer Institute, which started in the 1960s. Paclitaxel was identified from Pacific yew tree Taxus brevifolia. Paclitaxel showed anti-tumour activity by a previously undescribed mechanism (stabilization of microtubules) and is now approved for clinical use for the treatment of lung, breast, and ovarian cancer, as well as for Kaposi's sarcoma. Early in the 21st century, Cabazitaxel (made by Sanofi, a French firm), another relative of taxol has been shown effective against prostate cancer, also because it works by preventing the formation of microtubules, which pull the chromosomes apart in dividing cells (such as cancer cells). Other examples are: 1.
===== Mass Spectrometry ===== Mass spectrometry methods are unable to determine the folding of nascent polypeptides. No current methods examine the folding states of nascent polypeptides globally in the cell. There are methods for examining the folding state of individual nascent polypeptides. One method uses a nonspecific protease to cleave the nascent peptide at a low temperature. The protease can cleave the unfolded, flexible regions, but cannot cut tightly folded regions. The products of the cleavage can then be separated and studied to determine the folded regions of the nascent peptide.
Sources: en.wikipedia.org
November 20, 2009: Mexico The Mexican government declared that its economy technically had left the recession when the Mexican GDP grew by 2.93% in the third quarter of 2009. Mexico had been in a severe economic crisis for over a year prior to its economic rebound. The Mexican government also approved a $244 billion budget for 2010, a slight increase from 2009.
==== Progressive multiple sclerosis ==== In 2011, mitoxantrone was the first medication approved for secondary progressive MS. In this population, tentative evidence supports mitoxantrone moderately slowing the progression of the disease and decreasing rates of relapses over two years. In 2026, tolebrutinib, a BTK inhibitor, was approved for non-relapsing secondary MS in the EU. It reduces the activity of microglia, immune cells in the brain, as well as of B cells. New approved medications continue to emerge. In March 2017, the FDA approved ocrelizumab as a treatment for primary progressive MS in adults, the first drug to gain that approval. It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. According to a 2021 Cochrane review, ocrelizumab may reduce worsening of symptoms for primary progressive MS and probably increases unwanted effects but makes little or no difference to the number of serious unwanted effects. In 2019, siponimod and cladribine were approved in the United States for the treatment of secondary progressive multiple sclerosis (SPMS). Subsequently, ozanimod was approved in 2020, and ponesimod was approved in 2021, which were both approved for management of CIS, relapsing MS, and SPMS in the U.S., and RRMS in Europe. Ocrelizumab/hyaluronidase was approved for medical use in the United States in September 2024.
==== The possibility of using two mixtures in the synthesis ==== In principle, the use of two mixtures in the S&P synthesis can lead to the same combinatorial library that forms in the usual S&P method. The differences in the reactivity of BBs however, bring about large differences in the concentrations of components, and the differences are expected to increase after each step. Although a considerable amount of labor could be saved by using the two mixtures approach when a high number of BBs are coupled in each position, it is advisable to stick to the normally used S&P procedure.
=== Os cordis === In some animals, the fibrous trigone can undergo increasing mineralization with age, leading to the formation of a significant os cordis (heart bone), or two (os cordis sinistrum and os cordis dextrum, the latter being the larger one). The os cordis is thought to serve mechanical functions. In humans, two paired trigones (left and right) are seen in this essential view of anatomy. As a surgical purchase point, the Trigones risk much in AV propagation. It has been known since Classical times in deer and oxen and was thought to have medicinal properties and mystical properties. It is occasionally observed in many other artiodactyls including goats, sheep, giraffes, camels, water buffalo, and antelopes but also in carnivorans such as otters, dogs, cats, and sea lions and in the horse. It has also been discovered in chimpanzees, the first known great ape to have an os cordis; it has subsequently been reported in a human, though its etiology is unknown. Against the opinion of his time, Galen wrote that the os cordis was also found in elephants. While it is unclear if Galen actually observed the bone, it has since been identified in Asian elephants.
Membranous glomerulonephritis may cause either nephrotic or a nephritic picture. About two-thirds are associated with auto-antibodies to phospholipase A2 receptor, but other associations include cancers of the lung and bowel, infections such as hepatitis B and malaria, drugs including penicillamine, and connective tissue diseases such as systemic lupus erythematosus. Individuals with cerebral shunts are at risk of developing shunt nephritis, which frequently produces MGN. Microscopically, MGN is characterized by a thickened glomerular basement membrane without a hyperproliferation of the glomerular cells. Immunofluorescence demonstrates diffuse granular uptake of IgG. The basement membrane may completely surround the granular deposits, forming a "spike and dome" pattern. Tubules also display the symptoms of a typical Type III hypersensitivity reaction, which causes the endothelial cells to proliferate, which can be seen under a light microscope with a PAS stain. Prognosis follows the rule of thirds: one-third remain with MGN indefinitely, one-third remit, and one-third progress to end-stage kidney failure. As the glomerulonephritis progresses, the tubules of the kidney become infected, leading to atrophy and hyalinisation. The kidney appears to shrink. Treatment with corticosteroids is attempted if the disease progresses. In extremely rare cases, the disease has been known to run in families, usually passed down through the females. This condition, similarly, is called Familial Membranous Glomerulonephritis. There have only been about nine documented cases in the world.
Sources: en.wikipedia.org
Organometallic complexes analogous to uranocene are known also for other actinides, such as thorium, protactinium, neptunium, plutonium and americium. Molecular orbital theory predicts a stable "curocene" complex (η8-C8H8)2Cm, but it has not been reported experimentally yet. Formation of the complexes of the type Cm(n-C3H7-BTP)3 (BTP = 2,6-di(1,2,4-triazin-3-yl)pyridine), in solutions containing n-C3H7-BTP and Cm3+ ions has been confirmed by EXAFS. Some of these BTP-type complexes selectively interact with curium and thus are useful for separating it from lanthanides and another actinides. Dissolved Cm3+ ions bind with many organic compounds, such as hydroxamic acid, urea, fluorescein and adenosine triphosphate. Many of these compounds are related to biological activity of various microorganisms. The resulting complexes show strong yellow-orange emission under UV light excitation, which is convenient not only for their detection, but also for studying interactions between the Cm3+ ion and the ligands via changes in the half-life (of the order ~0.1 ms) and spectrum of the fluorescence. There are a few reports on biosorption of Cm3+ by bacteria and archaea, and in the laboratory both americium and curium were found to support the growth of methylotrophs.
=== Food === E. sinensis has a high protein content, so in some areas of China are used as food, and considered to be a delicacy by some. Traditionally only adult females are used medicinally and as food, due to the belief that females have better nutritional content compared to males. Recent research has found that nutritional composition varies by sex and life stage. When comparing males and females directly one is not inherently better than the other, their compositions are different but both valuable. Average protein content for E. sinensis was found to be 57.25 ± 6.12%, this is higher than most other edible insects, milk and eggs, but not quite as high as pork and beef. Nymph protein was significantly lower than adults. Fat content was comparable to that of pork and Orthoptera, ranging from 15.70 ± 0.78% to 18.89 ± 0.31%, but interestingly lower than other species within Blattodea. They are also a good source of essential minerals and amino acids. E. sinensis is often described as having a strong fishy odor, and has a salty taste.
In the spring of 1948, Liu Wenhui's son Yuanyan, who was studying at West China University and had secretly come into contact with the Communist Youth League, came to Liu to act as an intermediary for negotiations with the Communist Party. However, Liu Wenhui told his son that he had already been in contact with the communists. This contact had happened in 1942, when Liu met with Zhou Enlai in Chongqing to discuss forming an anti-Chiang Kai-shek pact. Liu and Zhou reportedly agreed to jointly resist Chiang and to share intelligence; in a concession to the Xikang warlord, the communists also promised not to organize within Liu's 24th Army. This pact was exemplified by the existence of a covert communist radio station in Ya'an, established in June 1942 under the leadership of Wang Shaochun. This radio station provided Liu with pro-communist battle reports and propaganda, and operated continuously until 1949, helping coordinate the Chengdu Uprising. In 1947, after the Nationalists captured Yan'an and put the communist forces on the backfoot, Liu temporarily stopped providing funding to the radio station; however, he resumed support soon after. Zhou Enlai described Liu as a "political thermometer", who was "sometimes hot, sometimes cold" in his dealings with the Communist Party.
Platelets contain dense granules, lambda granules, and alpha granules. Activated platelets secrete the contents of these granules through their canalicular systems to the exterior. Bound and activated platelets degranulate to release platelet chemotactic agents to attract more platelets to the site of endothelial injury. Granule characteristics:
=== Directly affiliated enterprises === China Agricultural Production Materials Group Corporation China Cotton Group Co., Ltd. China Renewable Resources Development Co., Ltd. New Cooperative Trade Chain Group Co., Ltd. China Supply and Marketing E-commerce Co., Ltd. Beijing National Cotton Trading Market Co., Ltd. China Supply and Marketing Agricultural Products Wholesale Market Holdings Co., Ltd. China Supply and Marketing Cold Chain Logistics Co., Ltd. China Supply and Marketing Benefiting Agriculture Service Effective Company China Supply and Marketing Grain and Oil Co., Ltd. Supply and Marketing Group Finance Co., Ltd. New Supply and Marketing Industry Development Fund Management Co., Ltd.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。